Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

PURPOSE: BRAF mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of epidermal growth factor receptor (EGFR) signaling occurs in colorectal tumor cells treated with RAF i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Yaeger, Rona, Cercek, Andrea, O'Reilly, Eileen M., Reidy, Diane L., Kemeny, Nancy, Wolinsky, Tamar, Capanu, Marinela, Gollub, Marc J., Rosen, Neal, Berger, Michael F., Lacouture, Mario E., Vakiani, Efsevia, Saltz, Leonard
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546416/
https://ncbi.nlm.nih.gov/pubmed/25589621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2779
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires